Smiths Group (“Smiths”) confirms that it is contracting with the UK Government for a significant ramp up in the production of its life saving Smiths Medical paraPAC plus™ ventilators. Production will rapidly increase from hundreds a month to thousands a month to fulfil 10,000 units in response to the UK Government’s challenge to UK technology and engineering businesses to help save lives in the coronavirus pandemic.
The paraPAC plus™ lightweight and portable ventilators deliver oxygen to the lungs of sick patients to help them breathe, taking some of the strain from the lungs, during emergencies, when transported to and around medical facilities, or wherever they are needed. The device is fully certified and used by medical professionals within the UK and overseas.
Smiths is working closely with the Ventilator Challenge UK Consortium to expand its supply chain capability, including Smiths own operations in Luton and many other leading UK Technology and Engineering companies across automotive, aerospace, industrial and F1.
In addition, Smiths Group confirms it is also in urgent discussions with potential partners around the world to make its ventilator technology available to support the global fight against Covid-19.
Andrew Reynolds Smith, CEO of Smiths Group commented:
“It is our duty and an honour to be supporting the UK Government to save as many lives as possible. We are playing a key role working with the Ventilator Challenge UK Consortium to put in place the production and component capability to increase manufacturing of our lightweight portable ventilator as fast as possible.
It is inspiring to work with the very best UK Technology and Engineering companies with a spirit of grit and determination to deliver these life saving devices to our incredible health service. I am proud of the tireless work that our people at Smiths and those working across this extraordinary consortium of British companies are doing to make a real difference.
Outside of the UK, we are also supporting the global fight, and are working hard with consortia and governments across the world to make our ventilator technology available to them.”
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.